Aberrant tetranectin expression in human breast carcinomas as a predictor of survival

Journal of Clinical Pathology

Volumn 57, Issue 4, 2004, Pages 417-421

  Obrist, P ^a   Spizzo, G ^a   Ensinger, C ^a   Fong, D ^a   Brunhuber, T ^a   Schafer G ^a   Varga, M ^a   Margreiter, R ^b   Amberger, A ^b   Gastl, G ^a   Christiansen, M ^c  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN; TETRANECTIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER INVASION; CANCER SURVIVAL; CONNECTIVE TISSUE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; METASTASIS; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; REGULATORY MECHANISM; RETROSPECTIVE STUDY; TUMOR CELL; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LECTINS, C-TYPE; MIDDLE AGED; PROGNOSIS;

EID: 11144358014     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.010058     Document Type: Article

References (42)

1. Durkin ME, Naylor SL, Albrechtsen R, et al. Assignment of the gene for human tetranectin (TNA) to chromosome 3p22→p21.3 by somatic cell hybrid mapping. Cytogenet Cell Genet 1997;76:39-40.
2. Nielsen BB, Kastrup JS, Rasmussen H, et al. Crystallization and molecular-replacement solution of a truncated form of human recombinant tetranectin. Acta Crystallogr D Biol Crystallogr 2000;56:637-9.
3. Fuhlendorff J, Clemmensen I, Magnusson S. Primary structure of tetranectin, a plasminogen kringle 4 binding plasma protein: homology with asialoglycoprotein receptors and cartilage proteoglycan core protein. Biochemistry 1987;26:6757-64.
4. Jaquinod M, Holtet TL, Etzerodt M, et al. Mass spectrometric characterisation of post-translational modification and genetic variation in human tetranectin. Biol Chem 1999;380:1307-14.
5. Clemmensen I. Interaction of tetranectin with sulphated polysaccharides and trypan blue. Scand J Clin Lab Invest 1989;49:719-25.
6. Lorentsen RH, Graversen JH, Caterer NR, et al. The heparin-binding site in tetranectin is located in the N-terminal region and binding does not involve the carbohydrate recognition domain. Biochem J 2000;347:83-7.
7. Kluft C, Jie AF, Los P, et al. Functional analogy between lipoprotein(a) and plasminogen in the binding to the kringle 4 binding protein, tetranectin. Biochem Biophys Res Commun 1989;161:427-33.
8. Kluft C, Los P, Clemmensen I, et al. Quantitation of plasma levels of tetranectin - effects of oral contraceptives, pregnancy, treatment with L-asparaginase and liver cirrhosis. Thromb Haemost 1989;62:792-6.
9. Nielsen H, Clemmensen I, Kharazmi A. Tetranectin: a novel secretory protein from human monocytes. Scand J Immunol 1993;37:39-42.
10. Borregaard N, Christensen L, Bejerrum OW, et al. Identification of a highly mobilizable subset of human neutrophil intracellular vesicles that contains tetranectin and latent alkaline phosphatase. J Clin Invest 1990;85:408-16.
11. Clemmensen I, Lund LR, Christensen L, et al. A tetranectin-related protein is produced and deposited in extracellular matrix by human embryonal fibroblasts. Eur J Biochem 1991;195:735-41.
12. Wewer UM, Ibo K, Durkin ME, et al. Tetranectin is a novel marker for myogenesis during embryonic development, muscle regeneration, and muscle cell differentiation in vitro. Dev Biol 1998;200:247-59.
13. Wewer UM, Iboraki K, Schjorring P, et al. A potential role for tetranectin in mineralization during osteogenesis. J Cell Biol 1994;127:1767-75.
14. Kamper EF, Kopeikina L, Mantas A, et al. Tetranectin levels in patients with acute myocardial infarction and their alterations during thrombolytic treatment. Ann Clin Biochem 1998;35:400-7.
15. Christensen L, Johansen N, Jensen BA, et al. Immunohistochemical localization of a novel, human plasma protein, tetranectin, in human endocrine tissues. Histochemistry 1987;87:195-9.
16. Christensen L, Clemmensen I. Differences in tetranectin immunoreactivity between benign and malignant breast tissue. Histochemistry 1991;95:427-33.
17. Arvanitis DL, Kamper EF, Kopeikina L, et al. Tetranectin expression in gastric adenocarcinomas. Histol Histopathol 2002;17:471-5.
18. De Vries TJ, De Wit PE, Clemmensen I, et al. Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions. J Pathol 1996;179:260-5.
19. Blaakaer J, Hogdall CK, Micic S, et al. Ovarian carcinoma serum markers and ovarian steroid activity - is there a link in ovarian cancer? A correlation of inhibin, tetranectin and CA-125 to ovarian activity and the gonadotropin levels. Eur J Obstet Gynecol Reprod Biol 1995;59:53-6.
20. Hogdall CK, Hogdall EV, Hording U, et al. Plasma tetranectin and ovarian neoplasms. Gynecol Oncol 1991;43:103-7.
21. Skriver L, Nielsen LS, Kristensen P, et al. [Biochemical mechanism for extracellular proteolysis. Tissue destruction and cancer.] Nord Med 1983;98:238-41.
22. Jensen BA, Clemmensen I. Plasma tetranectin is reduced in cancer and related to metastasia. Cancer 1988;62:869-72.
23. Hogdall CK, Mogensen O, Tabor A, et al. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors. Gynecol Oncol 1995;56:22-8.
24. Hogdall CK, Hording U, Norgaard-Pedersen B, et al. Serum tetranectin and CA-125 used to monitor the course of treatment in ovarian cancer patients. Eur J Obstet Gynecol Reprod Biol 1994;57:175-8.
25. Hogdall CK, Christensen L, Clemmensen I. [Tetranectin, a plasma and tissue protein-a prognostic marker of breast and ovarian cancer.] Ugeskr Laeger 1994;156:6190-5.
26. Hogdall CK, Hogdall EV, Hording U, et al. Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients. Scand J Clin Lab Invest 1993;53:741-6.
27. Hogdall CK, Christensen L, Clemmensen I. The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. Cancer 1993;72:2415-22.
28. Hogdall CK, Christiansen M, Christensen L, et al. Monoclonal antibodies against human tetranectin, epitope characterization and use in immunohistochemistry. Clin Chim Acta 1997;258:159-77.
29. Clemmensen I, Petersen LC, Kluft C. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 1986;156:327-33.
30. Iba K, Durkin ME, Johnsen L, et al. Mice with a targeted deletion of the tetranectin gene exhibit a spinal deformity. Mol Cell Biol 2001;21;7817-25.
31. Schmitt M, Janicke F, Graerff H. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul Fibrinolysis 1990;1:695-702.
32. Bell WR. The fibrinolytic system in neaplasia. Semin Triromb Hemost 1996;22:459-78.
33. Dano K, Andreasen PA, Grondahl-Hansen J, et al. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985;44:139-266.
34. Dvorak HF, Dickersin GR, Dvorak AM, et al. Human breast carcinoma: fibrin deposits and desmoplasia. Inflammatory cell type and distribution. Microvasculature and infarction. J Natl Cancer Inst 1981;67:335-45.
35. Flaumenhaft R, Abe M, Mignatti P, et al. Basic fibroblast growth factor-induced activation of latent transforming growth factor beta in endothelial cells: regulation of plasminogen activator activity. J Cell Biol 1992;118:901-9.
36. Lundstrom MS, Hogdall CK, Nielsen AL, et al. Serum tetranectin and CA125 in endometrial adenocarcinoma. Anticancer Res 2000;20:3903-6.
37. Deng X, Hogdall EV, Hogdall CK, et al. The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer. Gynecol Oncol 2000;79:416-19.
38. Hogdall CK, Christiansen M, Norgaard-Pedersen B, et al. Plasma tetranectin and colorectal cancer. Eur J Cancer 1995;31A:888-94.
39. Hogdall CK, Soletormos G, Nielsen D, et al. Prognostic value of serum tetranectin in patients with metastatic breast cancer. Acta Oncol 1993;32:631-6.
40. Sumiyoshi K, Serizawa K, Urano T, et al. Plasminogen activator system in human breast cancer. Int J Cancer 1992;50:345-8.
41. Christensen L, Clemmensen I. Tetranectin immunoreactivity in normal human tissues. An immunohistochemical study of exocrine epithelia and mesenchyme. Histochemistry 1989;92:29-35.
42. Costantini V, Zacharski LR, Memoli VA, et al. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. Cancer Res 1991;51:354-8.